We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Drugmakers and others in the pharmaceutical supply chain still have much overhauling of shipping and verification systems and processes to do if they are to meet the Nov. 27 deadline for Drug Supply Chain Security Act (DSCSA) compliance, a new report says. Read More
Catalyst Pharmaceuticals has filed a lawsuit against Lupin Pharmaceuticals alleging that Lupin’s proposed generic of Firdapse (amifampridine) runs afoul of patent rights for the Lambert-Eaton myasthenic syndrome (LEMS) drug. Read More
Eisai pushed back yesterday against price cut recommendations by the Institute for Clinical and Evidence Review (ICER) for its Alzheimer’s treatment Leqembi (lecanemab), saying that the company had already reduced the drug’s price below what its own models indicated to be a fair price. Read More
In the midst of swirling controversy about high insulin prices, Eli Lilly has announced that it’s reducing the cost of its most commonly prescribed — and older — insulins by 70 percent and expanding its program that caps patient out-of-pocket costs at $35 per month. Read More
The plaintiffs are seeking injunctions against the generics makers barring them from marketing alternatives to Yupelri until the expiration of patent protections, as well as damages. Read More
AstraZeneca has announced plans to extend its oncology drug portfolio through a licensing deal with KYM Biosciences for an investigational antibody-drug conjugate (ADC) for treatment of gastric cancer. Read More
Theravance Biopharma and Viatris have alleged that multiple drugmakers infringed on their patent protections for Yupelri (revefenacin) — an inhalation solution used to treat chronic obstructive pulmonary disease (COPD) — by developing generic versions of the drug. Read More